BioCryst Pharmaceuticals, Inc.BCRXNASDAQ
Loading
Year-over-year earnings per share growth rate
Latest
1805.54%
↑ 12261% vs avg
Percentile
P100
Near historical high
Streak
2 qtr
Consecutive growthAccelerating
Average
14.61%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 1805.54% |
| Q3 2025 | 207.00% |
| Q2 2025 | 0.00% |
| Q1 2025 | 100.00% |
| Q4 2024 | -85.71% |
| Q3 2024 | -16.67% |
| Q2 2024 | 64.71% |
| Q1 2024 | 45.16% |
| Q4 2023 | -63.16% |
| Q3 2023 | 52.50% |
| Q2 2023 | -42.86% |
| Q1 2023 | 26.32% |
| Q4 2022 | -65.22% |
| Q3 2022 | 28.13% |
| Q2 2022 | 20.00% |
| Q1 2022 | -309.00% |
| Q4 2021 | 70.36% |
| Q3 2021 | -37.50% |
| Q2 2021 | 33.33% |
| Q1 2021 | -5.88% |
| Q4 2020 | -30.77% |
| Q3 2020 | -8.33% |
| Q2 2020 | 0.00% |
| Q1 2020 | -1100.00% |
| Q4 2019 | 94.12% |
| Q3 2019 | 0.00% |
| Q2 2019 | -21.43% |
| Q1 2019 | -12.00% |
| Q4 2018 | 10.71% |
| Q3 2018 | -47.37% |
| Q2 2018 | 26.92% |
| Q1 2018 | -30.00% |
| Q4 2017 | -11.11% |
| Q3 2017 | 14.29% |
| Q2 2017 | -10.53% |
| Q1 2017 | -211.48% |
| Q4 2016 | 61.88% |
| Q3 2016 | 27.27% |
| Q2 2016 | 29.03% |
| Q1 2016 | -24.00% |